The insider sales are routine post-exercise dispositions and do not signal management concern. Focus on the strong MYQORZO launch trajectory and upcoming PDUFA date (Nov 14, 2026) for MAPLE-HCM as key catalysts. Monitor next quarter's prescription growth and cash burn rate.
Price Chart
Executive Summary
Two insiders at Cytokinetics sold a combined $2.39M in open-market stock on May 5, 2026, the same day the company reported strong Q1 2026 earnings highlighting a successful MYQORZO launch and positive ACACIA-HCM trial results. The sales represent ~0.03% of the $8.2B market cap, making them trivial in size and likely routine post-exercise dispositions rather than a bearish signal.
Key Financial Metrics
Key Facts
- Two insiders sold a total of $2.39M in open-market stock on May 5, 2026
- Sales represent ~0.03% of CYTK's $8.2B market cap
- Both sales were preceded by derivative exercises (non-cash or at low strike prices)
- Q1 2026 earnings reported same day: MYQORZO net product revenue of $4.8M, total revenue $19.4M vs $1.6M YoY
- ACACIA-HCM trial met dual primary endpoints in non-obstructive HCM
- Cash position $1.1B as of March 31, 2026
Financial Impact
Insider sales of $2.39M are immaterial relative to $8.2B market cap
Risk Factors
- Cash burn of $144M in Q1 2026 may require future capital raise
- Commercial execution risk as MYQORZO launch scales
- Regulatory risk ahead of MAPLE-HCM PDUFA date
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1778012192019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access